16
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      U.K. utility weights for the EORTC QLU-C10D.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The EORTC QLU-C10D is a new multi-attribute utility instrument derived from the widely used cancer-specific quality of life questionnaire, EORTC QLQ-C30. It contains 10 dimensions (physical functioning, role functioning, social functioning, emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems), each with four levels. The aim of this study was to provide U.K. general population utility weights for the QLU-C10D. A U.K. online panel was quota-sampled to align the sample to the general population proportions of sex and age (≥18 years). The online valuation survey included a discrete choice experiment (DCE). Each participant was asked to complete 16 choice-pairs, each comprising two QLU-C10D health states plus duration. DCE data were analysed using conditional logistic regression to generate utility weights. Data from 2,187 respondents who completed at least one choice set were included in the DCE analysis. The final U.K. QLU-C10D utility weights comprised decrements for each level of each health dimension. For nine of the 10 dimensions (all except appetite), the expected monotonic pattern was observed across levels: Utility decreased as severity increased. For the final model, consistent monotonicity was achieved by merging inconsistent adjacent levels for appetite. The largest utility decrements were associated with physical functioning and pain. The worst possible health state (the worst level of each dimension) is -0.083, which is considered slightly worse than being dead. The U.K.-specific utility weights will enable cost-utility analysis (CUA) for the economic evaluation of new oncology therapies and technologies in the United Kingdom, where CUA is commonly used to inform resource allocation.

          Related collections

          Author and article information

          Journal
          Health Econ
          Health economics
          Wiley
          1099-1050
          1057-9230
          December 2019
          : 28
          : 12
          Affiliations
          [1 ] School of Public Health, Curtin University, Perth, Western Australia, Australia.
          [2 ] University of Sydney, Faculty of Science, School of Psychology, Sydney, New South Wales, Australia.
          [3 ] NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia.
          [4 ] School of Health and Related Research, University of Sheffield, Sheffield, UK.
          [5 ] Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
          [6 ] Department of Pharmacy Systems, Outcomes and Policy, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois.
          [7 ] Centre for Health Economics Research and Evaluation (CHERE), University of Technology Sydney, Sydney, New South Wales, Australia.
          [8 ] Patient-Centered Research, Evidera, Bethesda, Maryland.
          Article
          10.1002/hec.3950
          31482619
          f62da33a-803d-418c-95fe-9a7baa000169
          History

          cancer,discrete choice experiment,health state valuation,utility

          Comments

          Comment on this article